BioSpace News Archive

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense System of minimally-invasive cryoablation technology that destroys tumors by freezing, today reported audited financial results as of and for the twelve months ended December 31, 2022.

Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, announced their metabolomics platform outputs and related services have been cited in more than 3,000 peer-reviewed journals.

Harmony Biosciences Holdings, Inc. today announced an accelerated timeline for completing its Phase 3 INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH).

Massive Bio, which uses artificial intelligence and concierge service to match cancer patients to oncology clinical trials regardless of their location or financial circumstances, continues its expansion beyond the United States.

The Institute for Protein Innovation will host IPI Surfacing, a symposium on cell surface receptor biology, on Thursday, June 15, 2023.

Establishment Labs Holdings Inc. announced that it has surpassed three million Motiva ® devices in market.

Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Navi Singh Parmar, Michaela Scheiner, and Dr. Sanam Sikander-Rehman as leaders in Prescient Medical.

Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA).

Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription.

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) today announced its financial results for the year and quarter ended December 31, 2022.